6-K ·Filed Jun 24, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001395064-26-000181
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine AGM outcome filing with no new financial data or strategic catalysts. Monitor the next earnings release or 20-F for fundamental updates. The dividend is confirmed but unchanged from prior expectations.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
TAK ▲ +21.18% at T+60d
NEUTRAL call ✓ call won +21.18% · α vs SPY +18.35% · entry $15.72 → $19.05
Entry anchored
Jun 23, 03:59 PM ET
via exchange tick
T+1d
-0.45%
call -0.45% · α -0.59%
$15.65
settled 3mo ago
T+5d
+1.46%
call +1.46% · α -0.24%
$15.95
settled 3mo ago
T+20d
+7.32%
call +7.32% · α +5.38%
$16.87
settled 2mo ago
T+60d
+21.18%
call +21.18% · α +18.35%
$19.05
settled 14d ago

Price Chart

Loading chart...

Executive Summary

Takeda filed a 6-K reporting resolutions from its 150th Annual General Meeting of Shareholders. Key outcomes include approval of a year-end dividend of 100 JPY per share, re-election of six directors, and election of two new directors (Julie Kim and Paul Stoffels) as non-Audit and Supervisory Committee Members, plus two new ASC directors. The filing is routine governance with no material financial data or strategic changes.

Key Facts

  • Year-end dividend of 100 JPY per share approved.
  • Eight directors (non-ASC) re-elected or newly elected, including Julie Kim and Paul Stoffels.
  • Three ASC directors re-elected or newly elected, all external.
  • Director bonuses capped at 260 million JPY total for two eligible directors.
  • No financial results, guidance, or material business developments disclosed.

Financial Impact

Dividend of 100 JPY per share; director bonus pool of 260 million JPY (approx. $1.7M at current rates). No revenue, earnings, or other financial figures provided.

dividend

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001395064-26-000181
Document: 0001395064-26-000181-index-headers.html0001395064-26-000181
Document: 0001395064-26-000181-index.html0001395064-26-000181
Document: 0001395064-26-000181.txt0001395064-26-000181
13 reports for TAK
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TAK — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$18.60 $18.89▲ +1.56%▲ +1.45%$17.86 (−3.98%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.18 $18.03▼ −0.83%▼ −1.30%$17.86 (−1.76%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$18.34 $18.23▼ −0.60%▼ −0.21%$17.86 (−2.62%)
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 4/10
$17.63 $18.18▲ +3.12%▲ +4.49%$17.86 (+1.30%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Aug 13, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$17.39 $18.13▲ +4.26%▲ +6.22%$17.86 (+2.70%)
Jul 9, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.61 $16.73▲ +0.72%▲ +0.85%$17.86 (+7.53%)
Jul 8, 2026
12w ago
6-K
NEUTRAL ★ 2/10
$16.75 $16.39▼ −2.15%▼ −3.01%$17.86 (+6.63%)
Jul 6, 2026
12w ago
3
NEUTRAL ★ 2/10
$16.89 $16.56▼ −1.95%▼ −2.44%$17.86 (+5.74%)
Jun 29, 2026
13w ago
6-K
NEUTRAL ★ 2/10
$15.98 $16.89▲ +5.69%▲ +4.31%$17.86 (+11.76%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access